enGene Holdings Inc. (NASDAQ:ENGN) Receives $11.05 Consensus Target Price from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has received a consensus recommendation of “Hold” from the fourteen analysts that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $11.0455.

A number of analysts have recently issued reports on the company. HC Wainwright reduced their target price on enGene from $6.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Leerink Partners downgraded enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price target on the stock. in a report on Friday, May 8th. Raymond James Financial lowered enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price target on the stock. in a research report on Friday, May 8th. Morgan Stanley downgraded enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective for the company. in a research note on Thursday, June 18th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $2.00 price objective (down from $25.00) on shares of enGene in a research report on Friday, May 8th.

Institutional Trading of enGene

A number of hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC increased its stake in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after buying an additional 3,771,840 shares during the period. Siren L.L.C. acquired a new stake in shares of enGene during the 4th quarter valued at $30,126,000. Janus Henderson Group PLC purchased a new position in shares of enGene during the 4th quarter valued at $17,110,000. Cormorant Asset Management LP grew its holdings in shares of enGene by 72.1% during the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after acquiring an additional 1,676,405 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of enGene by 7,214.0% in the fourth quarter. Millennium Management LLC now owns 1,499,520 shares of the company’s stock worth $13,541,000 after acquiring an additional 1,479,018 shares during the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Stock Performance

enGene stock opened at $1.79 on Wednesday. enGene has a fifty-two week low of $1.40 and a fifty-two week high of $12.25. The firm’s 50 day simple moving average is $1.78 and its 200-day simple moving average is $5.60. The company has a debt-to-equity ratio of 0.10, a current ratio of 12.57 and a quick ratio of 12.57. The company has a market cap of $119.91 million, a P/E ratio of -0.82 and a beta of -0.28.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Monday, June 15th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05. During the same quarter in the previous year, the company posted $0.51 earnings per share. As a group, equities research analysts predict that enGene will post -1.84 EPS for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.